A newly published cache of CRLs includes six novel oncology drugs.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
PD-(L)1 x VEGF bispecifics prove a big draw.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Some big deals in the second quarter have raised hopes that takeouts are back.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
